Previous 10 | Next 10 |
2023-05-19 15:00:19 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week, or the Seeking Alpha earnings calendar ...
2023-05-18 18:51:15 ET Summary Verona Pharma plc's Ensifentrine is the first drug that combines bronchodilation and anti-inflammatory effects in COPD. Phase 3 data showed that the drug showed a 40% pooled reduction in the rate of exacerbations compared to the placebo. Verona P...
2023-05-13 10:11:06 ET Verona Pharma plc (VRNA) Q1 2023 Earnings Conference Call May 9, 2023 9:00 AM ET Company Participants David Zaccardelli - President and Chief Executive Officer Mark Hahn - Chief Financial Officer Kathleen Rickard - Chief Medical Officer ...
2023-05-09 02:12:39 ET Verona Pharma press release ( NASDAQ: VRNA ): Q1 GAAP EPS of -$0.03 beats by $0.08 . Cash and cash equivalents at March 31, 2023, were $291.4 million (December 31, 2022: $227.8 million). The company believes cash and cash equivalents at March...
NDA submission on schedule for Q2 2023 12 abstracts and one symposium expanding on successful Phase 3 ENHANCE data to be presented at American Thoracic Society 2023 Strong balance sheet to support commercial launch preparations Conference call today at 9:00 a.m. EDT / 2:...
12 Abstracts and one Symposium further support potential of ensifentrine, a first-in-class, selective, dual inhibitor of PDE3 and PDE4 Conference call May 23 at 4:00 p.m. EDT / 9:00 p.m. BST LONDON and RALEIGH, N.C., May 02, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: ...
LONDON and RALEIGH, N.C., April 25, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the fir...
2023-04-24 05:31:06 ET Summary Biotech stocks have been consolidating recently but may be ready to rally higher due to factors such as a declining 10-year yield and growing M&A activity. Biotech deal-making has been increasing, with large acquisitions such as Pfizer's acquisit...
2023-04-16 01:22:24 ET Summary Regeneron's Dupixent reported a 30% reduction in COPD exacerbation at week 52, while ensifentrine reported a 36% and 42% reduction in the ENHANCE-1 and ENHANCE-2 trials, respectively. Ensifentrine's broader inclusion criteria and lower cost as a smal...
LONDON and RALEIGH, N.C., April 10, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its development partner, Nuance Pharma, has dosed the...
News, Short Squeeze, Breakout and More Instantly...
2024-07-05 11:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-27 07:00:04 ET Raghuram Selvaraju from H.C. Wainwright issued a price target of $36.00 for VRNA on 2024-06-27 06:09:00. The adjusted price target was set to $36.00. At the time of the announcement, VRNA was trading at $14.69. The overall price target consensus is...
Ohtuvayre is indicated for the maintenance treatment of COPD allowing for broad use in COPD patients First inhaled COPD treatment providing bronchodilation and non-steroidal anti-inflammatory effects Conference call tomorrow at 8:30 a.m. EDT / 1:30 p.m. BST LONDON and RALEIG...